Your Science Is at Stage 3. Your Quality System Is at Stage 1.

How product stage plans build the quality foundation your pipeline actually needs

Most biotech and pharma companies don't fail at science. They fail at the handoffs.

GLP to GMP. Research to development. Development to manufacturing. Each stage transition is a minefield of undocumented processes, unvalidated methods, and supplier relationships that were never properly qualified.

And yet, quality infrastructure is almost always the last thing companies think about — and the first thing that bites them when it matters most.

I've spent 13+ years in FDA and EPA-regulated environments watching organizations sprint toward IND submissions or commercial launch, only to hit a wall because their quality systems weren't built for where they were going. Only for where they'd been.

The solution isn't to build everything at once. It's to build the right things at the right time. That's what a product stage plan, anchored by a stage-appropriate quality strategy, is designed to do.

What Is a Product Stage Plan — and Why Does Quality Belong In It?

A product stage plan maps out the critical milestones, requirements, and infrastructure your organization needs at each phase of development: early research, preclinical, clinical, and commercial. In regulated industries, this plan doesn't just cover science and timelines — it must account for the quality systems that govern how data is generated, reviewed, retained, and defended.

Quality infrastructure, if not planned alongside product development, inevitably becomes reactive. You end up retrofitting SOPs, scrambling to qualify vendors before a CMC submission, or discovering data integrity gaps during an FDA inspection instead of an internal audit.

A well-designed product stage plan answers a deceptively simple question: what does our quality system need to look like at each stage to support the science, protect the data, and satisfy regulators?

The Three Stages Where Quality Infrastructure Gets Built — or Broken

Stage 1: Early Development (GLP and Pre-GMP)

This is where the foundation gets poured. Organizations at this stage are often small, fast-moving, and understandably focused on getting data. But the quality decisions made here — or not made — echo forward.

In GLP-regulated environments, the priority is establishing compliant documentation practices, ensuring data integrity from the start, and setting up a study management framework that holds up under audit. The specific requirements depend on whether you're conducting GLP environmental studies, toxicology work, or analytical method development — but the underlying need is the same: a defensible record of how the science was done.

What stage-appropriate quality looks like here:

• GLP-compliant SOPs for key laboratory operations

• Data integrity controls (raw data retention, audit trails, access management)

• A deviation management process, even if informal

• An understanding of which studies will require GLP compliance and which will not

Stage 2: IND-Enabling Studies and GMP Transition

This is where most quality systems get tested — and where many fall apart. The transition from GLP to GMP is not just a regulatory checkbox. It requires a fundamental rearchitecting of how quality is embedded into operations.

GMP introduces requirements around batch records, equipment qualification, change control, CAPA systems, and product release — none of which have direct analogues in a GLP environment.

Organizations that haven't planned for this transition often find themselves trying to build a GMP-compliant QMS while simultaneously running IND-enabling studies, managing CMO relationships, and preparing regulatory submissions.

What stage-appropriate quality looks like here:

• QMS architecture that is designed for GMP, not retrofitted from GLP

• Change control and deviation management procedures that scale

• CMO/CRO qualification: quality agreements, audit programs, oversight cadence

• Method validation planning aligned to ICH guidelines

• Batch record templates and product release workflows

Stage 3: Clinical Manufacturing, Scale-Up, and Commercial Readiness

By this stage, your quality system needs to be not just functional, but inspection-ready. FDA investigators, EMA assessors, and other regulators are evaluating not only whether your SOPs exist — but whether your organization actually lives by them.

This stage is also where supplier and CMO relationships become high-stakes. A quality failure at a contract manufacturer doesn't stay at the CMO — it becomes your problem, your warning letter, your clinical hold.

What stage-appropriate quality looks like here:

• CAPA systems with demonstrated effectiveness verification

• Supplier audit programs with documented findings and follow-through

• Internal audit schedules and inspection readiness simulations

• Annual Product Reviews and quality metrics reporting

• Regulatory submission support: CMC sections, responses to deficiencies

The "Cathedral" Principle: Build for Where You're Going

You don't have to build the whole cathedral on day one. But you do need to pour the right foundation.

One of the most common mistakes I see is organizations either over-building early (creating GMP-level infrastructure before it's needed, draining resources without regulatory benefit) or under-building (deferring quality investments until they become emergency remediation projects). Both are costly. Both are avoidable.

A stage plan built with quality in mind identifies:

• Which quality elements are required now versus which can be deferred

• Where informal processes need to be formalized before the next regulatory gate

• Which vendor and CMO relationships require qualification before they create risk

• What documentation needs to exist — and in what form — to support your next filing

This is not about creating bureaucracy for its own sake. It's about making deliberate, right-sized decisions so that your quality infrastructure grows with your pipeline instead of racing to catch up with it.

How Foundry Quality Group Helps at Every Stage

At Foundry Quality Group, I work with biotech, pharmaceutical, and agricultural life sciences companies to design and implement quality systems that are matched to where they are — and built for where they're going.

Whether you're navigating your first GLP study, preparing for a GMP transition, qualifying a CMO ahead of a clinical program, or getting ready for your first FDA inspection, I bring the experience of having built and maintained quality systems from the ground up in regulated environments — and zero critical findings to show for it.

My services span the full development lifecycle:

• QMS architecture and implementation (from scratch or remediation)

• GLP-to-GMP transition planning

• CMO and vendor qualification, auditing, and oversight

• CAPA system design and effectiveness review

• Inspection readiness preparation

• Documentation systems: SOPs, batch records, quality agreements

Every stage has its own playbook. The goal of a product stage plan is to make sure you're running the right one.

Ready to align your quality infrastructure with your pipeline?

If your organization is navigating a stage transition and your quality system feels like it's catching up instead of leading, let's talk. I'd love to hear where you are and help you map out where you need to be.